União Europeia - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - fingolimod cloridrato - sclerosi multipla recidivante-remittente - immunosoppressori selettivi immunosoppressori - indicato come monoterapia disease-modifying terapia altamente attiva recidivante remittente della sclerosi multipla per i seguenti gruppi di pazienti adulti e pazienti pediatrici di età compresa tra i 10 anni e gli anziani:i pazienti con altamente attiva di malattia nonostante un completo e adeguato corso di trattamento con almeno una malattia modifica therapyorpatients con rapida evoluzione grave, recidivante remittente della sclerosi multipla definita da 2 o più invalidante recidive in un anno, e con 1 o più gadolinio migliorare lesioni alla risonanza magnetica cerebrale o un aumento significativo della lesione t2 carico rispetto ad un precedente recente rm.

União Europeia - italiano - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mieloma multiplo - agenti antineoplastici - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

União Europeia - italiano - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - mieloma multiplo - agenti antineoplastici - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

União Europeia - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - fampridine - sclerosi multipla - altri farmaci sul sistema nervoso - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).

União Europeia - italiano - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - sclerosi multipla recidivante-remittente - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

União Europeia - italiano - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - sclerosi multipla recidivante-remittente - immunosoppressori - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

União Europeia - italiano - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - mieloma multiplo - agenti antineoplastici - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

União Europeia - italiano - EMA (European Medicines Agency)

mylan ireland limited - fingolimod cloridrato - sclerosi multipla recidivante-remittente - immunosoppressori - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 e 5. 1)orpatients con rapida evoluzione grave, recidivante remittente della sclerosi multipla definita da 2 o più invalidante recidive in un anno, e con 1 o più gadolinio migliorare lesioni alla risonanza magnetica cerebrale o un aumento significativo della lesione t2 carico rispetto ad un precedente recente rm.

Suíça - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

ferring ag - menotropinum - soluzione iniettabile in penna preriempita - menotropinum 600 u.i., arginini hydrochloridum, methioninum, polysorbatum 20, phenolum, natrii hydroxidum aut acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 0.96 ml corresp. natrium 14.2 µg. - stimolazione del follikelwachstums in caso di infertilità - biotechnologika

Suíça - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

ferring ag - menotropinum - soluzione iniettabile in penna preriempita - menotropinum 1200 u.i., arginini hydrochloridum, methioninum, polysorbatum 20, phenolum, natrii hydroxidum aut acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 1.92 ml corresp. natrium 14.2 µg. - stimolazione del follikelwachstums in caso di infertilità - biotechnologika